Summary
The influence of pentoxifylline on normal and diseased neutrophil function has been studied in vitro. In high concentrations pentoxifylline stimulated human neutrophil chemotaxis toward both bacterial oligopeptides and complement components. Pentoxifylline was also shown in vitro to restore the normal chemotactic capacity of neutrophils from patients with known functional defects, i.e. myelodysplastic syndromes, lazy leucocyte syndrome, juvenile parodontitis, hyper-IgE-syndrome and liver cirrhosis. Pentoxifylline was also shown to strongly inhibit the release of primary and secundary granule release of granulocytes. Moreover, pentoxifylline inhibits both basal and stimulated neutrophil adhesion to both aortic and pulmonary artery calf endothelium. The mechanism whereby pentoxifylline exerts this action is not adequately understood. While our results partially imply interference of pentoxifylline with neutrophil cyclic AMP and/or prostaglandin metabolism, down-regulation of neutrophil functional antigen (e.g. CD11, CD18) expression seems to play a key role in the observed drug effects. Finally, these results indicate that pentoxifylline may be useful in the treatment of granulocyte mediated diseases and symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boogaerts MA, Yamada O, Jacob HS, Moldow CF (1982) Enhancement of granulocyte-endothelial cell adherence and granulocyte induced cytotoxicity by platelet release products. Proc Natl Acad Sci USA 79: 7019–7023
Boogaerts MA, Nelissen V, Roelant C, Goossens W (1983) Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 55: 217–227
Boogaerts MA, Vercelotti G, Roelant C, Verwilghen RL, Jacob HS (1986) Importance of platelet free granulocyte preparations as shown by improved cell separation techniques. Scand J Haematol 37: 229–236
Boogaerts MA, Roelant C, Zachee P, Goossens W, Verwilghen RL (1986) Complement activation and adult respiratory distress syndrome during intermittent flow apheresis procedures. Transfusion 26: 82–87
Chatelet LR, Wang P, McCall F (1972) Hexose monophosphate shunt activity and O2-consumption during phagocytosis. Proc Soc Exp Biol Med 140: 1434–1437
Fehr J, Jacob HS (1977) In vitro granulocyte adherence and in vivo margination, two associated complement dependent functions. J Exp Med 146: 641–652
Fishman WH, Springer B, Brunetti R (1948) Application of an improved glucuronidase assay method to the study of human blood beta-glucuronidase. J Biol Chem 173: 449
Goldstein IM, Roos D, Kaplan HB, Weisman G (1975) Complement and immunoglobulin stimulate superoxyde production by human leukocytes independently of phagocytosis. J Clin Invest 56: 1155–1160
Heilmann E, Zimmerman R, Gruss P (1982) Effect of pentoxifylline on hypercoagulability in patients with polycythemia vera. IRCS Med Sci 10: 594–595
Hopkins NK, Gorman KR (1981) Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin. J Clin Invest 67: 540–546
Keller F, Leonhardt M (1979) Amelioration of blood viscosity in sickle cell anemia by pentoxifylline. J Med 10: 429–431
Klebanoff SJ, Clark RA (1978) The neutrophil: function and clinical disorders. North Holland Amsterdam, pp 5–72
Muller R (1979) Pentoxifylline, a biomedical profile. J Med 10: 307–329
Nelson RD, Quie PG, Simmons RL (1975) Chemotaxis under agarose: a new and simple method for measuring chemotaxis and spontaneous migration of human polymorphonuclear leukocytes and monocytes. J Immunol 115: 1650–1656
Nelson RD, Herron MJ, Schmidtke R, Simmons L (1977) Chemiluminescence response of human leukocytes: influence of medium components on light production. Infect Immun 17: 513–516
Ott E, Fazekas F, Valetitsch M (1986) The rationale of rheological pharmacological therapy. Clin Hemorheol 6: 35–40
Poggesi L, Scarti L, Boddi M, Masotti G, Serneri G (1985) Pentoxifyllin treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis. Angiology 36: 628–636
Pohanka E, Sinzinger E (1986) Effect of a single pentoxifyllin administration on platelet sensitivity, plasma factor activity, plasma 6-keto-PGF1 alpha and thromboxane B2 in healthy volunteers. Prostaglandines Leukotrienes Med 22: 191–200
Pohlman TH, Stanners RA, Beatty PG, Ocks HD, Harlan JM (1986) An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1 and tumor necrosis factor increased neutrophil adherence by a CDW-18 dependent mechanism. J Immunol 136: 4548–4553
Schade UF, Schonharting M (1986) Effects of pentoxifylline on the endotoxin induced shock reaction. Clin Hemorheol 6: 462
Schmalzer EA, Chion S (1984) Filterability of subpopulations of leukocytes: effect of pentoxifylline. Blood 64: 542–546
Smolelis AN, Hartsell SE (1949) The determination of lysozyme. J Bacteriol 58: 731–736
Stefanovich V (1978) The biochemical mechanism of action of pentoxifyllin. Pharmatherapeutica 2: 5–16
Strano A, Davi G, Avellone G, Novo S, Pinto A (1984) Double blind, cross-over study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35: 439–446
Tan JS, Watanakuwakora C, Phair JP (1971) A modified assay of neutrophil function: use of lysostaphin to differentiate defective phagocytosis from impaired intracellular killing. J Lab Clin Med 78: 316–322
Yamada O, Moldow CF, Boogaerts MA, Jacob HS (1981) Deleterious effects of endotoxin on cultured endothelial cells: an in vitro model of vascular injury. Inflammation 5: 115–126
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boogaerts, M.A., Malbrain, S., Meeus, P. et al. In vitro modulation of normal and diseased human neutrophil function by pentoxifylline. Blut 61, 60–65 (1990). https://doi.org/10.1007/BF02076701
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02076701